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ABSTRACT
Objective: Guillain–Barré syndrome (GBS) case definitions have been developed in recent past for its quick diagnosis.
However, they have not been adopted worldwide especially in developing countries like Pakistan. In this study, we
validated the sensitivity of Brighton working group case definitions for GBS at Services Hospital Lahore. Methods: A total
of 30 cases of GBS with available clinical history, neurological examination,cerebrospinal fluid(CSF) and nerve conduction
studies (NCS) results, and exclusion of related diagnoses were selected (2014–2015). Sensitivity of the Brighton criteria
for GBS for level 3 of diagnostic certainty which requires no clinical laboratory testing, level 2 which employs CSF or NCS,
and level 1 which employs both, were calculated. Results: All the 30 cases of GBS (mean age 37±16 years, range
16-62; 31% females) met the GBS case definitions. These cases were characterized as AIDP (30%), AMSAN (56.7%),
AMAN (5%) involving lower extremity hypotonia and weakness (100%), upper extremity hypotonia and weakness (100%),
areflexia (82.8) and hyporeflexia (17.2%). Four limbs were involved in almost all the cases (100%). CSF (mean time to
lumbar puncture 29 days) was not found normal in any case with cytoalbuminologic dissociation in 100% (mean protein
105 mg/dL, range 10–1000; mean cell count 11/µL, range 0–50s, with <50 cells/µL). The majority of cases (88%)
fulfilled Brighton level 1 (88%), level 2 (10%), and level 3 (2%) of diagnostic certainty. Conclusion: In conclusion, GBS
diagnosis using Brighton Working Group criteria can be made successfully in developing countries like Pakistan with
moderate to higher sensitivity.
Key Words: Guillain–Barré syndrome; Brighton criteria; Validation; Pakistan
INTRODUCTION

Miller Fisher syndrome (MFS), which is characterized by
ophthalmoplegia, ataxia and areflexia.4 Overall, the clinical
course, severity and outcomes of GBS are highly variable.
GBS typically occurs after an infectious disease in which
the immune response generates antibodies that
crossreact with gangliosides at nerve membranes. This
autoimmune response results in nerve damage or
functional blockade of nerve conduction. True and early
diagnosis of GBS could impact on its prognosis, as the
benefit of immunotherapy is greatest when introduced
early, in the first few weeks of disease.2 In November,
2005, a Brighton Collaboration GBS Working Group was
established with a total of 34 members from different
backgrounds including public health, regulatory, clinical
and academic, and industry. The Working Group identified
the key clinical and epidemiologic features required for
diagnosis of GBS.4 Some previous studies (e.g. Sejvar et
al.4 and Mateen et al.7) have reported these guidelines as
useful tool for the correct diagnosis of GBS and its major
subtypes. In the present study, we have aimed to test the
validity of guidelines of Brighton working group criteria in
the diagnosis of GBS in local settings of Pakistan.

Guillain–Barré syndrome (GBS) is a common cause of
acute flaccid paralysis, characterized by symmetrical
weakness of the limbs, and hyporeflexia or areflexia, which
reaches a maximum severity within 4 weeks. Sensory
symptoms, such as paraesthesia or numbness, usually
start distally and have a symmetrical pattern. It is an
immune mediated disorder of peripheral nerves with
incidence of 1-2 cases per 100,000 populations.1,2 and is
more common in men than in women (ratio 3:2).3
Worldwide, its incidence and prevalence vary; for example,
a low rate of 0.40 per 100,000 person–years was
reported in Brazil, in contrast to a high rate of 2.5 per
100,000 person–years in Curaçao and Bangladesh.3 GBS
seems to occur less frequently in children (0.34–1.34 per
100,000 person– years) than in adults, and its incidence
increases with age. Based on electrophysiological findings,
the most common subtypes of GBS are acute
inflammatory demyelinating polyneuropathy (AIDP), acute
motor axonal neuropathy (AMAN) and acute motor sensory
axonal neuropathy (AMSAN). A less common subtype is
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MATERIALS AND METHODS

cerebrospinal fluid examination, and radiographs for each
case were also conducted as per discretion of the treating
physicians. The Brighton Collaboration GBS Working
Group 2010 guidelines reported in Sejvar et al.4 were
applied to each case (see Table 1). All cases in which GBS
was considered to be the final diagnosis and met our
inclusion criteria of having both CSF and NCS were
analyzed for sensitivity.

The present study was conducted in Department of
Neurology at Services Institute of Medical Sciences and
Services Hospital, Lahore, Pakistan. This prospective
1-year study (from July 2014 to July 2015) identified 30
patients who were admitted with the primary diagnosis of
Guillain Barré Syndrome (GBS). The study included the
patients of all ages with no diabetes diagnosis and
excluded the patients with concurrent factors (drug
addiction, alcohol intake) and having weaknesses due to
diseases other than GBS. The patients were also excluded
with Fisher syndrome.

Statistical Analyses
The descriptive statistical analysis included examinations
of means, standard deviations, frequencies, ranges, and
percentages. Sensitivity was defined as the proportion of
all cases of GBS meeting the given criteria of interest out
of the total number of cases with CSF and NCS diagnosed
with GBS. The statistical packages SPSS (Version 20) and
MS Excel (MS Office 2010) were used.

Table 1. List of Brighton Working group clinical case
definitions: Guillain–Barré syndrome. (Adapted from
Sejvar et al.4)
Level 1 of
diagnostic
certainity

Level 2 of
diagnostic
certainity

Level 3 of
diagnostic
certainity

The presence of
Acute onset of bilateral and relatively symmetric flaccid
weakness/paralysis of the limbs
Decreased or absent deep tendon reflexes at least in affected limbs
Monophasic illness pattern, with weakness nadir reached between 12h
and 28 days, followed by clinical plateau and subsequent improvement,
or death
Electrophysiologic findings consistent with GBS
Presence of cytoalbuminologic dissociation (elevation of cerebrospinal
fluid (CSF) protein level above laboratory normal value, and CSF total
white cell count <50 cells/µl)
Absence of an alternative diagnosis for weakness
The presence of
Acute onset of bilateral and relatively symmetric flaccid
weakness/paralysis of the limbs
Decreased or absent deep tendon reflexes at least in affected limbs
Monophasic illness pattern, with weakness nadir reached between 12h
and 28 days, followed by clinical plateau and subsequent improvement,
or death
Cerebrospinal fluid (CSF) with a total white cell count <50
cells/mm3(with or without CSF protein elevation above laboratory
normal value)
IF CSF not collected or results not available, electrodiagnostic studies
consistent with GBS
Absence of an alternative diagnosis for weakness
The presence of
Acute onset of bilateral and relatively symmetric flaccid
weakness/paralysis of the limbs
Decreased or absent deep tendon reflexes at least in affected limbs
Monophasic illness pattern, with weakness nadir reached between 12h
and 28 days, followed by clinical plateau and subsequent improvement,
or death
Absence of an alternative diagnosis for weakness

RESULTS
Demographics and severity of weakness:
Over one year of period (2014-2015), a total of 30
patients admitted in department of neurology who were
categorized with GBS. These cases were reviewed in detail
during this period. In all of the 30 patients, cerebrospinal
fluid analysis (CSF) and nerve conduction studies (NCS)
were performed. All the patients studied were
predominately came from Punjab region of Pakistan and
disease incidence was reported during almost all the
seasons of the year. Mean age of the admitted cases of
GBS was 37±16 years with a range of 16-62. Males were
greater in number (70%) and male to female ratio was
2:2.1 in present study. The details of studied cases
including their demographic characteristics and clinical
features are listed in Table 2. All the GBS cases reported in
present study were classified into four major sub-groups on
the basis of electrophysiological pattern of nerve
conduction studies (Figure 1), as AIDP (30%), AMSAN
(56.7%), AMAN (5%) and Equivocal (8.3%). Acute
inflammatory demyelinating polyneuropathy and acute
motor sensory axonal neuropathy were the predominant
subtypes. Out of all, more than 86% of the patients
switched between these two conditions. Cerebrospinal fluid
(CSF) was categorized as normal (protein between 15 and
45mg/dL, cell count ≤5/mL, glucose ≥2/3 of serum
glucose or within normal laboratory range) or abnormal at
the time of first lumbar puncture.6 Increased levels of
protein in cerebrospinal fluids without increase in cell count
was found in almost all cases and albuminocytological
dissociation was in 100% of the cases. Brighton criteria for
level 1 was met by 88% of the patients, for level 2 by 10%
and only 2% for level 3 (Figure 2).

We fulfilled the diagnostic criteria from the National
Institute of Neurological Disorders and Stroke (NINDS)
from 1990.5 The diagnosis of GBS in these patients was
made on the basis of clinical presentation, CSF findings,
electromyography and nerve conduction studies. A
structured questionnaire was used to record the following
demographic and clinical variables as part of this study:
sex, date of birth, place of residence, date and site of AFP
onset, number of limbs affected at nadir, presence of
fever, clinical descriptive history, and complete
neurological examination. Each patient’s nerve
conduction study report including data and wave forms
was reviewed by at least one qualified neurologist and
assigned a classification based on the criteria published
by the Plasma Exchange/ Sandoglobulin Guillain–Barré
Syndrome Trial Group (1998).6 In addition, blood studies,
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Table 2. Demographic and clinical characteristics of all
GBS patients studied.
Characteristics
Female (% cases)
Male to Female ratio
Mean age ± SD (range)
All limbs affected (%)
Mean time to maximal weakness
Hypotonia (%)
Areflexia (%)
Hyporeflexia (%)
Symmetrical weakness (%)
Ascending weakness (%)
Cerebrospinal fluid examination
Protein concentration > normal value

reached the nadir of their disease within a month. At
admission, 83% of the patients had a symmetrical limb
weakness and 17% had reduced reflexes in all limbs.
During disease progression, all patients developed
reduced reflexes in the legs, although a few patients
retained upper limb reflexes throughout their illness
despite arm weakness. All patients with an examination of
the CSF showed a cell count < 50 cells/ml and almost all
nerve conduction studies showed evidence for a
neuropathy. Until 1990, the high variability of
Guillain-Barre Syndrome had been reported by many
authors, including variants, and overlap syndromes, with
an equally large variation in type of preceding infections
and specificity of antibodies to nerve glycolipids.9,10 It
was in 2009, when Brighton working group criteria
presented more valid criteria with GBS case definitions to
better identify the patients.4 Better and fast identification
of GBS patients by this criteria led to timely and proper
management and for vaccine safety studies. The major
advantages of the Brighton criteria are the clear and
detailed case definitions and the classification in four
levels of diagnostic certainty depending on the patient
characteristics and the availability of the data.8 The GBS
can be diagnosed in developing countries like Pakistan by
using Brighton Working Group criteria. A good number of
clinically diagnosed GBS cases in present study met the
basic clinical definition of GBS. Out of 30, 27 (88%) of the
patients could be classified as level 1. High percentage of
reaching to this level was a protein concentration in CSF
which was higher than normal in 100% of the patients.
Fokke et al.4 reported only 61% diagnostic values for level
1. They attributed this low percentage to a normal protein
concentration in CSF (33%). Other causes were a
prolonged phase of 428 days (2%), and the absence of a
monophasic disease course (clinical deterioration beyond
8 weeks of onset of weakness) (4%). However, level 3 of
the Brighton criteria is dependent only on clinical criteria
and does not rely on additional investigations. This
category was designed particularly with resource-poor
settings in mind, in situations where electrophysiological
and CSF examination may be difficult, and/or unavailable.
Our study emphasized that accurate and thorough
documentation of clinical signs should allow for better
classification of Guillain-Barre syndrome in developing
countries. In some countries such as in Netherlands,
additional investigations such as CSF examination or
serial nerve physiology may not be conducted routinely in
clinical practice if alternative diagnoses could be trusted.4
Although incidence of all forms of AFP is significant in
developing countries including Pakistan and India, the
incidence of GBS in Pakistan has not been reported
widely. In 1968 from a tertiary care center in India,
Chhuttani et al.11 reported the clinical features of 63
patients with GBS out of a total of 710 peripheral
neuropathy patients observed from 1953 to 1965. Case

Value
31
2:2.1
37±16 (16-62)
100
15 days
>80
82.8
17.2
100
100
100%

Figure 1. Electrophysiological pattern of GBS on nerve
conduction studies.
NCS Results
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Figure 2. Graph showing the sensitivity of Brighton
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DISCUSSION
The present study evaluated the clinical, electro
physiological and laboratory features in 30 adult patients
diagnosed with Guillain-Barre syndrome. The diagnostic
criteria for Guillain-Barre syndrome developed by the
NINDS in 1990 were met by the patients with certain
caveats.5 In our study, almost 98.9% of the patients
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level 1, level 2 (10%), and level 3 (2%) of diagnostic
certainty. In conclusion, GBS diagnosis using Brighton
Working Group criteria can be made successfully in local
settings of Pakistan.

fatality was 28.5%. More recent clinical studies have
found a high incidence of cranial nerve palsies (76%) in
children, respiratory paralysis (40%), and lower case
fatalities (11-16%).12 The relative predominance of
electrophysiological subtypes of GBS is known to differ
geographically. Asian populations, including cohorts in
Japan and China, demonstrate axonal predominance
compared to the demyelinating subtype which is most
common in Western populations.13 In our study, the
demyelinating subtype (30%) and axonal subtype (56%)
were seen. This finding is also in contrast to a recent study
conducted in India that reported AIDP (25%) subtype to
be more common compared to ASMAN (18%).7 Further
studies in Pakistan would be of interest to delineate which
electrophysiological patterns predominate at different
ages, regions, and socio-economic levels. Patients in
whom the diagnosis of GBS is uncertain may require both
NCS and CSF analyses in order to rule out alternative
etiologic diagnoses for clinical purposes. Brighton criteria
are designed for monitoring, evaluation, and surveillance
rather than guiding the care of an individual hospitalized
patient. It is possible that milder cases of GBS are not
reported since they get managed before reaching medical
attention. Diagnosis of GBS Brighton Working Group
criteria will become increasingly important in Pakistan and
other developing countries as we mentioned in our study.
As poliomyelitis eradication is achieved and widespread
vaccination continues, the relative burden and need to
monitor and report GBS will also rise. A field-tested,
pragmatic, validated, and sensitive case definition of GBS
will help achieve monitoring in times of both active and
AFP surveillance.
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CONCLUSION
This study aimed to validate Brighton working group
criteria for GBS diagnosis in local settings of Pakistan. We
conclude that Brighton criteria for GBS diagnosis can be
used with acceptable sensitivity for level 3 of diagnostic
certainty which requires no clinical laboratory testing, level
2 which employs CSF or NCS, and level 1 which employs
both. In our study, 30 cases of GBS (mean age 37±16
years, range 16-62; 31% females) met the GBS case
definitions. GBS patients reported in Services hospital
Lahore can be classified according to following subtypes
of GBS: AIDP (30%), AMSAN (56.7%), AMAN (5%). These
patients have >80% areflexia and weakness of all four
limbs was shown in almost all the cases (100%) in our
study. CSF (mean time to lumbar puncture 29 days) was
not found normal in any case with cytoalbuminologic
dissociation in 100% (mean protein 105 mg/dL, range
10–1000; mean cell count 11/µL, range 0–50, with <50
cells/µL). The majority of cases (88%) fulfilled Brighton
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